Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Sadeleştirilmiş öğe sayfası
dc.contributor.authorEl Saghir, Nagi S.
dc.contributor.authorYap, Yoon Sim
dc.contributor.authorEralp, Yesim
dc.contributor.authorIm, Seock\\-Ah
dc.contributor.authorAzim, Hamdy A.
dc.contributor.authorRihani, Julie
dc.contributor.authorVolkov, Nikita
dc.contributor.authorChen, Shin\\-Cheh
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorSunpaweravong, Patrapim
dc.contributor.authorChang, Yuan\\-Ching
dc.contributor.authorAlfaro, Teresa Delgar
dc.contributor.authorWu, Jiwen
dc.contributor.authorHu, Huilin
dc.contributor.authorGao, Ming
dc.contributor.authorLu, Yen\\-Shen
dc.date.accessioned2025-10-16T15:15:20Z
dc.date.issued2023
dc.description.abstractAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, JUN 02-06, 2023
dc.identifier.otherWOS:001053772000174
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6419
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleOutcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS